Therapeutic agents targetting protein-protein interactions: Myth or reality?;Des agents thérapeutiques ciblant des interactions protéine-protéine: Mythe ou réalité?

Medecine/Sciences

Volumn 23, Issue 3, 2007, Pages 273-278

  Laudet, Béatrice ^a   Prudent, Renaud ^a   Filhol, Odile ^a   Cochet, Claude ^a  

^a CEA GRENOBLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; X LINKED INHIBITOR OF APOPTOSIS;

CELL FUNCTION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

EID: 33947525447     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2007233273     Document Type: Review

References (41)

1. Lo Conte L, Chothia C, Janin J. The atomic structure of protein-protein recognition sites. J Mol Biol 1999 ; 285 : 2177-98.
2. Nooren IMA, Thornton JM. Structural characterization and functional significance of transient protein-protein interactions. J Mol Biol 2003 ; 325 : 991-1018.
3. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J Mol Biol 1998 ; 280 : 1-9.
4. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996 ; 274 : 948-53.
5. Teague SJ. Implication of protein flexibility for drug discovery. Nat Rev Drug Discov 2003 ; 2 : 527-41.
6. DeLano WL, Ultsch MH, de Vos AM, Wells JA. Convergent solutions to binding at a protein-protein interface. Science 2000 ; 287 : 1279-83.
7. Kim c, Xuong NH, Taylor SS. Crystal structure of a complex between the catalytic and regulatory (RIalpha) subunits of PKA. Science 2005 ; 307 : 690-6.
8. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004 ; 303 : 844-8.
9. Piehler J. New methodologies for measuring protein interactions in vivo and in vitro. Curr Opin Struct Biol 2005 ; 15 : 4-14.
10. Toby GG, Golemis EA. Using the yeast interaction trap and other two-hybrid-based approaches to study protein-protein interactions. Methods 2001 ; 24 : 201-17.
11. Serebriiskil IG, Kotova E. Analysis of protein-protein interactions utilizing dual bait yeast two-hybrid system. Meth Mol Biol 2004 ; 261 : 263-96.
12. Trugnan G, Fontanges P, Delautier D, Ait-Slimane T. FRAP, FLIP, FRET, BRET, FLIM, PRIM... De nouvelles techniques pour voir la vie en couleur ! Med Sci (Paris) 2004 ; 20 : 1027-34.
13. Pfleger KD, Eidne KA. Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat Methods 2006 ; 3 : 165-74.
14. Thaminy S, Miller J, Stagljar I. The split-ubiquitin membrane-based yeast two-hybrid system. Meth Mol Biol 2004 ; 261 : 297-312.
15. Hu CD, Kerpolla TK. Simultaneous visualization of multiple protein interactions in living cells using multicolour fluorescence complementation analysis. Nat Biotechnol 2003 ; 21 : 539-45.
16. Lebowitz J, Lewis MS, Schuck P. Modern analytical ultracentrifugation in protein science: a tutorial review. Protein Sci 2002 ; 11 : 2067-79.
17. Karlsson R, Falt A. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J Immunol Methods 1997 ; 200 : 121-33.
18. Pierce MM, Raman CS, Nall BT. Isothermal titration calorimetry of protein-protein interactions. Methods 1999 ; 19 : 213-21.
19. Kay LE. NMR studies of protein structure and dynamics. J Magn Resonance 2005; 173: 193-207.
20. Dauter Z. Current state and prospects of macromolecular crystallography. Acta Crystallographica D Biol Crystallogr 2006 ; 62 : 1-11.
21. Erlanson DA, McDowell RS, O'Brien T. Fragment-based drug discovery. J Med Chem 2004 ; 47 : 3463-82.
22. Wermuth CG. Les grandes méthodes de découverte sont-elles appropriées ? Biofutur 2003 ; 239 : 23-7.
23. Kitov PI, Sadowska JM, Mulvey G, et al. Shiga-like toxins are neutralized by tailored multivalent ligands. Nature 2000 ; 403 : 669-72.
24. Verma R, Peters NR, D'Onofrio M, et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 2004 ; 306 : 117-20.
25. Luo C, Laaja P. Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov Today 2004 ; 9 : 268-75.
26. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541. A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004 ; 5 : 231-8.
27. Song M, Rajesh S, Hayashi Y, Kiso Y. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates. Bioorg Med Chem Lett 2001 ; 11 : 2465-8.
28. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 2000 ; 19 : 6627-31.
29. Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997 ; 275 : 983-6.
30. Degterev A, Lugovskoy A, Cardone M, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001 ; 3 : 173-82.
31. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005 ; 435 : 677-81.
32. Bilim V, Kasahara T, Hara N, et al. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 2003 ; 103 : 29-37.
33. Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000 ; 102 : 33-42.
34. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002 ; 8 : 808-15.
35. Liu Z, Sun C, Olejniczak ET, et al. Structural basis for binding of Smac/Diablo to the XIAP BIR3 domain. Nature 2000 ; 408 : 1004-8.
36. Li L, Thomas RM, Suzuki H, et al. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004 ; 305 : 1471-4.
37. Bottger A, Bottger V, Sparks A, et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 1997 ; 7 : 860-9.
38. Mukherjee AK, Basu S, Sarkar N, Ghosh AC. Advances in cancer therapy with plant based natural products. Curr Med Chem 2001 ; 8 : 1467-86.
39. Oost TK, Sun C, Armstrong RC, et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004 ; 47 : 4417-26.
40. Fasan R, Dias RL, Moehle K, et al. Structure-activity studies in a family of beta-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction. Chembiochem 2006 ; 7 : 515-26.
41. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera. A visualization system for exploratory research and analysis. J Comput Chem 2004 ; 25 : 1605-12.